Manni is the Director and Chief Executive Officer of GVK BIO. He joined GVK BIO in 2007 as President and has steered the company’s direction towards growth, to be one of Asia’s leading life sciences solutions organization.
Manni holds a Master of Science Degree in Computer Science from Arizona State University and a BE in Computer Engineering from Bombay University. He completed all his Ph.D. requirements and joined Intel prior to completing his dissertation.
Manni is also a Director and Chairperson on the Board of Aragen Bioscience, Inc., a fully owned subsidiary of GVK BIO, based in Morgan Hill, California, U.S.A. Prior to joining GVK BIO, Manni was in the IT industry, where he spent 16 years with Intel, holding various leadership positions in U.S.A and Asia. He served as the head of Intel India, the CIO of Intel for Asia and was responsible for the software in Intel’s Wi-Fi product line - Centrino.
Sudhir is the Chief Operating Officer of GVK BIO. He is responsible for the overall strategy, operations and business growth of the organization. He holds a Ph.D. in Medicinal Chemistry from Central Drug Research Institute, Lucknow. Sudhir has done his postdoctoral research work from SUNY College – Buffalo, New York; University of Alabama at Birmingham and Thomas Jefferson University, Philadelphia. He was also a part of the research and teaching teams at Rutgers, The State University of New Jersey, School of Pharmacy. He has several patents and scientific publications to his credit.
He joined GVK BIO in 2013 as Senior Vice President and brings 25 years of drug discovery and development experience to GVK BIO. Prior to GVK BIO, Sudhir was the Chief Operating Officer at Jubilant Chemsys Limited. He also held senior management positions at Aurigene Discovery Technologies and Ranbaxy Laboratories.
Ramesh is the CCO of GVK BIO. He has a Ph.D. in Chemical Engineering from West Virginia University, a B.Tech. in Chemical Engineering from IIT, Varanasi and an MBA in Finance from The Wharton School, University of Pennsylvania.
Ramesh is responsible for GVK BIO’s global sales, marketing, strategy and corporate development, including mergers and acquisitions (M&A). With over 20 years of experience in leadership roles, Ramesh has built global businesses in Asia and Europe, raised venture capital, established transformational strategies, drove M&A, negotiated cross-border deals and managed alliances.
Prior to joining GVK BIO, Ramesh served as the Senior Vice President and was a part of the management team at Piramal Pharma Solutions. Over his career, Ramesh has been part of management teams at Chemizon, a firm he led from start-up to successful entry into the equity markets, Jubilant Life Sciences and XL Advisors. Ramesh also held key leadership roles at SK Capital Partners/Ascend Performance Materials and Johnson Matthey.
As GVK BIO Chief Financial Officer, Sachin Dharap is responsible for corporate finance, business finance, accounting, M&A due diligence, risk management, treasury, taxation, legal and statutory compliances.
Sachin has 24 years of experience in various industries, both in India and abroad. Over the course of his career, he has served in different capacities at Abbott, Piramal Enterprises Ltd and Indian Oil Corporation Ltd. Prior to GVK BIO, Sachin has held various leadership positions including Commercial Director and Business Head, Abbott India, India Finance Director for Abbott Pharma and a Board position on Abbott’s listed arm (Abbott India Ltd). He was also involved in a few licensing and M&A projects, and led the finance module during Abbott India’s SAP implementation.
At Piramal, he was Vice President, Finance for its India Formulations business. His earlier roles at Piramal included Controller for its CMG business and Finance director for its UK operations. He was also accountable for the post-merger integration activities for business acquisitions in the UK.
Sachin is a certified Chartered Accountant from the Institute of Chartered Accountants of India and a certified Company Secretary from the Institute of Company Secretaries of India.
Suresh is the CHRO at GVK BIO, bringing more than 22 years of experience to the company. He holds a Bachelor’s Degree in Mechanical Engineering and a Post Graduate Diploma in Human Resources Management.
Suresh is responsible for envisioning and driving the human resources strategy in support of the business plan aimed at strategic direction of the organization.
Prior to GVK BIO, Suresh was the Director, HR at CA (India) Technologies Ltd., and played a crucial role in transforming the HR function to measurable, forward looking and value added function. He introduced new consultative and coaching approaches in building stronger business partnerships, People Capability Maturity Model frame work to improve processes, HRO/ RPO partnerships to enhance functional efficiency, M&A framework for seamless integration of acquired companies and HR analytics back office to predict people behaviour in order to take appropriate actions. Prior to CA (India) Technologies, Suresh worked at Symantec (India) Software Limited at their Pune location.
Dr. Axel Schleyer is the CEO of Aragen Bioscience, a wholly owned subsidiary of GVK BIO, based in the San Francisco Bay Area. Dr. Schleyer has completed his postdoctoral studies in a joint program with The Scripps Research Institute, La Jolla and Carlsberg Institute, Copenhagen. He received his Ph.D. in Chemistry, Molecular Biology from the University of Hamburg and his MBA from California State University, San Marcos. Dr. Schleyer brings a deep understanding of the pharmaceutical and biotechnology industry and related technologies to Aragen, including regulatory, CMC and GMP requirements.
Dr. Schleyer has over two decades of industry experience, building and leading high-performance teams, spearheading global business initiatives to formulate business strategies resulting in successful outcomes. Prior to joining Aragen Bioscience, Dr. Schleyer served as Senior Vice President at AGC Biologics. He has held senior positions with companies including Boehringer Ingelheim, Baxter Healthcare, Siegfried and Lonza.